This enrichment for PI3K/AKT/mTOR signaling in our study was validated with immunohistochemistry for phosphorylated AKT and in vitro cell culture assays evaluating tumor cell survival and proliferation following treatment with a PI3K inhibitor. This evidence concerns the gene AKT1 and neoplasm.